The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases
This study has been completed.
Sponsor:
Jonsson Comprehensive Cancer Center
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01180907
First received: August 11, 2010
Last updated: July 27, 2012
Last verified: July 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to determine whether positron emission tomography using the new imaging agent 18F-FAC can be used for imaging cancer and/or inflammation.
| Condition |
|---|
|
Cancer Inflammation |
| Study Type: | Observational |
| Official Title: | The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases: A Pilot Study |
Further study details as provided by Jonsson Comprehensive Cancer Center:
| Enrollment: | 10 |
| Study Start Date: | November 2007 |
| Primary Completion Date: | November 2011 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| patients with cancer |
| patients with autoimmune diseases |
| healthy subjects |
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
patients with cancer, autoimmune diseases and healthy subjects
Criteria
Inclusion Criteria:
- > 18 years of age
- women of childbearing potential will undergo a pregnancy test free of charge
- patients with cancer or autoimmune diseases or healthy subjects
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01180907
Please refer to this study by its ClinicalTrials.gov identifier: NCT01180907
Locations
| United States, California | |
| UCLA | |
| Los Angeles, California, United States, 90095 | |
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
Investigators
| Principal Investigator: | Christiaan Schiepers, M.D. Ph.D | University of California, Los Angeles |
More Information
| Responsible Party: | Jonsson Comprehensive Cancer Center |
| ClinicalTrials.gov Identifier: | NCT01180907 History of Changes |
| Other Study ID Numbers: |
07-07-071 DE-PS02-08ER-08-01 ( Other Grant/Funding Number: Department of Energy ) CIRMNo. RT1-01126-1 ( Other Grant/Funding Number: California Institute for Regenerative Medicine ) 10-000269 ( Other Identifier: UCLA Medical IRB#2 ) |
| Study First Received: | August 11, 2010 |
| Last Updated: | July 27, 2012 |
Keywords provided by Jonsson Comprehensive Cancer Center:
|
18F-FAC imaging cancer inflammation PET |
Additional relevant MeSH terms:
|
Inflammation Pathologic Processes |
ClinicalTrials.gov processed this record on May 24, 2017